We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights: Intel, Novartis, Toyota Motor, Union Pacific and Biogen
Read MoreHide Full Article
For Immediate Release
Chicago, IL – April 28, 2020 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Intel (INTC - Free Report) , Novartis (NVS - Free Report) , Toyota Motor (TM - Free Report) , Union Pacific (UNP - Free Report) and Biogen (BIIB - Free Report) .
Here are highlights from Monday’s Analyst Blog:
Top Research Reports for Intel, Novartis and Toyota
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Intel, Novartis and Toyota Motor. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
Intel’s shares have underperformed the Zacks General Semiconductor industry over the past six months (+3.7% vs. +11.5%). The Zacks analyst believes that robust mix of high-performance second-generation Xeon Scalable processors and solid demand from Cloud service providers is expected to drive near-term growth.
The company is also making advancements in the IoT space, courtesy of product introductions and tie ups. Moreover, Intel is witnessing strong momentum for its first 10-nanometer (nm) mobile CPU.
Notably, the company has not provided 2020 guidance citing coronavirus crisis-induced business uncertainty. Further, declining PC total addressable market, higher expenses pertaining to 10-nm ramp up and constrained supply amid coronavirus outbreak in China remain concerns.
Shares of Novartis have gained +11% over the past year against the Zacks Large Cap Pharmaceuticals industry’s rise of +12.4%. The Zacks analyst believes that pipeline setbacks and generic competition for additional drugs are concerning.
Novartis has a strong oncology portfolio and a formidable generics business. The solid performance of key drugs like Cosentyx and Entresto, and contribution from gene therapy, Zolgensma, have boosted the performance in recent times and offset the impact of generic competition for legacy drugs. New launches like Piqray, Mayzent and Beovu should further boost sales.
The biosimilar portfolio also gains traction with new key approvals. The deep pipeline is encouraging as well. Novartis is also focusing on developing treatments for coronavirus and a positive outcome will boost the stock significantly. However, price erosion in the United States has adversely impacted the generics business.
Toyota’s shares have lost -13.3% over the past three months against the Zacks Foreign Automotive industry’s fall of -18.4%. The Zacks analyst believes that expanding portfolio of product lines is driving Toyota’s prospects.
In order to capitalize on the accelerated global shift to electric cars, the auto giant of Japan is focusing on developing electric and autonomous vehicles. Toyota is working on hydrogen fuel stations in collaboration with various partners. The company aims to achieve half its global sales from electric vehicles by 2025. However, anticipating a slowdown in India, China, Indonesia and Thailand, the company narrowed its annual vehicle sales target for fiscal 2020.
Moreover, coronavirus woes and high research and development expenses on advanced technologies for the development of EVs and driverless cars are also likely to dent near-term margins. Its high debt levels also remain a concern. As such, investors are recommended to wait for a better entry point.
Other noteworthy reports we are featuring today include Union Pacific and Biogen.
Just Released: Zacks’ 7 Best Stocks for Today
Experts extracted 7 stocks from the list of 220 Zacks Rank #1 Strong Buys that has beaten the market more than 2X over with a stunning average gain of +24.1% per year.
These 7 were selected because of their superior potential for immediate breakout.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performancefor information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
The Zacks Analyst Blog Highlights: Intel, Novartis, Toyota Motor, Union Pacific and Biogen
For Immediate Release
Chicago, IL – April 28, 2020 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Intel (INTC - Free Report) , Novartis (NVS - Free Report) , Toyota Motor (TM - Free Report) , Union Pacific (UNP - Free Report) and Biogen (BIIB - Free Report) .
Here are highlights from Monday’s Analyst Blog:
Top Research Reports for Intel, Novartis and Toyota
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Intel, Novartis and Toyota Motor. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
Intel’s shares have underperformed the Zacks General Semiconductor industry over the past six months (+3.7% vs. +11.5%). The Zacks analyst believes that robust mix of high-performance second-generation Xeon Scalable processors and solid demand from Cloud service providers is expected to drive near-term growth.
The company is also making advancements in the IoT space, courtesy of product introductions and tie ups. Moreover, Intel is witnessing strong momentum for its first 10-nanometer (nm) mobile CPU.
Notably, the company has not provided 2020 guidance citing coronavirus crisis-induced business uncertainty. Further, declining PC total addressable market, higher expenses pertaining to 10-nm ramp up and constrained supply amid coronavirus outbreak in China remain concerns.
Shares of Novartis have gained +11% over the past year against the Zacks Large Cap Pharmaceuticals industry’s rise of +12.4%. The Zacks analyst believes that pipeline setbacks and generic competition for additional drugs are concerning.
Novartis has a strong oncology portfolio and a formidable generics business. The solid performance of key drugs like Cosentyx and Entresto, and contribution from gene therapy, Zolgensma, have boosted the performance in recent times and offset the impact of generic competition for legacy drugs. New launches like Piqray, Mayzent and Beovu should further boost sales.
The biosimilar portfolio also gains traction with new key approvals. The deep pipeline is encouraging as well. Novartis is also focusing on developing treatments for coronavirus and a positive outcome will boost the stock significantly. However, price erosion in the United States has adversely impacted the generics business.
Toyota’s shares have lost -13.3% over the past three months against the Zacks Foreign Automotive industry’s fall of -18.4%. The Zacks analyst believes that expanding portfolio of product lines is driving Toyota’s prospects.
In order to capitalize on the accelerated global shift to electric cars, the auto giant of Japan is focusing on developing electric and autonomous vehicles. Toyota is working on hydrogen fuel stations in collaboration with various partners. The company aims to achieve half its global sales from electric vehicles by 2025. However, anticipating a slowdown in India, China, Indonesia and Thailand, the company narrowed its annual vehicle sales target for fiscal 2020.
Moreover, coronavirus woes and high research and development expenses on advanced technologies for the development of EVs and driverless cars are also likely to dent near-term margins. Its high debt levels also remain a concern. As such, investors are recommended to wait for a better entry point.
Other noteworthy reports we are featuring today include Union Pacific and Biogen.
Just Released: Zacks’ 7 Best Stocks for Today
Experts extracted 7 stocks from the list of 220 Zacks Rank #1 Strong Buys that has beaten the market more than 2X over with a stunning average gain of +24.1% per year.
These 7 were selected because of their superior potential for immediate breakout.
See these time-sensitive tickers now >>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
http://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performancefor information about the performance numbers displayed in this press release.